Is Windtree Therapeutics Inc (WINT) Going to Burn These Hedge Funds?

Earlier we told you that the aggregate hedge fund interest in the stock was unchanged and we view this as a negative development. Even though there weren’t any hedge funds dumping their holdings during the third quarter, there weren’t any hedge funds initiating brand new positions. This indicates that hedge funds, at the very best, perceive this stock as dead money and they haven’t identified any viable catalysts that can attract investor attention.

Let’s now review hedge fund activity in other stocks similar to Windtree Therapeutics Inc (NASDAQ:WINT). These stocks are Triangle Petroleum Corporation (NYSEAMEX:TPLM), Provectus Biopharmaceuticals Inc (NYSEMKT:PVCT), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), and Acura Pharmaceuticals, Inc. (NASDAQ:ACUR). This group of stocks’ market values resemble WINT’s market value.

As you can see these stocks had an average of 4 hedge funds with bullish positions and the average amount invested in these stocks was $2 million. That figure was $7 million in WINT’s case. Triangle Petroleum Corporation (NYSEAMEX:TPLM) is the most popular stock in this table. On the other hand Provectus Biopharmaceuticals Inc (NYSEMKT:PVCT) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Windtree Therapeutics Inc (NASDAQ:WINT) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: none.